

Half-Year Report 2014



Dear Shareholders,

In the first six months of 2014, SHL Telemedicine has seen good momentum in its businesses leading to significantly improved financial performance for the period, even with the increased investments in our expansion initiatives. Expansion into new markets beyond Israel and Germany, based on our global smartheart™ platform, remains a key priority for SHL's growth strategy. We confirm our 2014 revenue guidance of over 30% growth year-over-year.

International expansion continues

In the U.S., we are progressing with our plans to launch our products and services, while in India we have made first steps in rolling out our telemedicine solution. In addition, since receiving approval in March to commence marketing activities in Japan, our smartheart platform has been accepted by over 20 leading Japanese clinics.

We have gone through a lengthy process of receiving regulatory and marketing approvals for the smartheart platform in several major territories. The global interest we are witnessing is very encouraging and we are excited by the opportunities it may bring.

Financial Highlights

During the second quarter 2014, revenues increased considerably, primarily due to the growth in the Company's German business, following the acquisition of almeda. Even with the increased investments in geographical expansion, SHL's financial performance has improved significantly with improved gross profit and operating results.

Revenues for the quarter grew by 39.2% (32.4% at constant exchange rates*) and amounted to USD 10.3 million compared to USD 7.4 million in Q2 2013. For the half year revenues grew by 44.1%

(37.2% at constant exchange rates) and amounted to USD 20.9 million compared to USD 14.5 million in the first half of 2013.

Gross profit for the quarter amounted to USD 5.8 million (56.3% of revenues) compared to USD 3.9 million (52.7% of revenues) in Q2 2013. Gross profit for the half year amounted to USD 11.7 million (56.0% of revenues) compared to a gross profit of USD 7.6 million (52.4% of revenues) in the first half of 2013.

EBITDA and **EBIT** for the half year and second quarter improved significantly over the adjusted EBITDA and EBIT of 2013, which included a one-time item lowering the general and administrative expenses.

For the quarter, EBITDA amounted to USD 1.7 million (16.5% of revenues) with EBIT at USD 0.2 million (1.9% of revenues) compared with an adjusted EBITDA and EBIT of USD 0.6 million and USD 0.7 million in the second quarter 2013.

For the half year, EBITDA amounted to USD 3.7 million (17.7% of revenues) with an EBIT of USD 0.6 million (2.9% of revenues), compared with an adjusted EBITDA of USD 0.5 million (3.4% of revenues) and an EBIT of USD 1.9 million in the first half of 2013.

Unadjusted EBITDA and EBIT for the second quarter 2013 amounted to USD 1.7 million and USD 0.4 million respectively, with EBITDA and EBIT for the first half of 2013 amounting to USD 3.1 million and USD 0.6 million, respectively.

Net Income for the quarter and half year was USD 0.1 million, or USD 0.01 per share, compared to an adjusted net loss of USD 1.1 million, for the second quarter 2013 and USD 2.8 million for the first half of 2013. Unadjusted net profit for the second quarter 2013 amounted to USD 0.1 million (USD 0.00 per share) and unadjusted net loss for the first half

2013 was USD 0.3 million (USD 0.03 per share), respectively.

Cash used in operations for the quarter and half year amounted to USD 0.9 million and USD 3.3 million, respectively. Excluding USD 5.2 million received from Philips in the first quarter of 2013, which was the last payment related to the Raytel transaction, cash used in operations during the quarter and half year 2013 amounted to USD 0.8 million and USD 1.9 million. The decrease in operating cash flow is the result of one-time working capital requirements at Alameda, for which SHL received USD 2.9 million upfront at the end of 2013. Cash, cash equivalents and marketable securities amounted to USD 21.8 million at June 30, 2014.

Balance sheet included total assets at 30 June 2014 of USD 106.3 million with shareholders' equity amounting to USD 68.8 million (64.7% of balance sheet) compared to total assets of USD 108.5 million with shareholders' equity amounting to USD 68.9 million at 31 December 2013.

The fact that in the first six months of this year SHL was able to achieve such good results in a fast changing environment reflects extremely well on our employees. We would like to thank them all on behalf of the Board of Directors and the management team for their outstanding work and dedication. We would like to thank all our customers and you, our valued shareholders, for your loyalty and your trust.

Sincerely,



Elon Shalev,

Chairman of the Board

INDEX

4		Report on Review of Interim Condensed Consolidated Financial Statements
5		Condensed Consolidated Balance Sheets
7		Condensed Consolidated Statements of Comprehensive Income (loss)
8		Condensed Consolidated Statements of Changes in Equity
10		Condensed Consolidated Statements of Cash Flows
13		Notes to Interim Condensed Consolidated Financial Statements

The Shareholders and Board of Directors SHL Telemedicine Ltd.

Re: Report on review of interim condensed consolidated financial statements

Introduction

We have reviewed the accompanying interim condensed consolidated financial statements of SHL Telemedicine Ltd. ("the Company") and its subsidiaries as of June 30, 2014, comprising the interim consolidated balance sheet as of June 30, 2014 and the related interim statement of comprehensive income, changes in equity and cash flows for the six months then ended and explanatory notes. Management is responsible for the preparation and presentation of these interim condensed consolidated financial statements in accordance with International Financial Reporting Standard IAS 34, "Interim Financial Reporting" ("IAS 34"). Our responsibility is to express a conclusion on these interim condensed consolidated financial statements based on our review.

Scope of review

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial

and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34.

Tel-Aviv, Israel

August 19, 2014

Kost Forer Gabbay and Kasierer

KOST FORER GABBAY & KASIERER

A Member of Ernst & Young Global

CONDENSED CONSOLIDATED BALANCE SHEETS U.S. dollars in thousands

	June 30,		December 31,
	2014	2013	2013
	Unaudited		Audited
ASSETS			
CURRENT ASSETS:			
Cash and cash equivalents	8,154	9,457	8,732
Restricted cash	1,365	-	-
Short term investments	12,301	18,091	19,661
Trade receivables	14,764	*) 12,495	10,479
Prepaid expenses	1,845	1,652	1,828
Inventory	1,628	475	869
Other accounts receivable	6,348	*) 4,944	6,186
	46,405	47,114	47,755
NON-CURRENT ASSETS:			
Prepaid expenses	5,494	5,117	5,239
Long-term deposits	201	192	203
Other accounts receivable	-	135	-
Deferred taxes	5,708	6,878	6,190
	11,403	12,322	11,632
PROPERTY AND EQUIPMENT:			
Cost	71,639	64,781	69,613
Less - accumulated depreciation	(55,939)	(49,656)	(53,631)
	15,700	15,125	15,982
GOODWILL	14,160	13,421	14,076
INTANGIBLE ASSETS, NET	18,633	9,871	19,070
Total assets	106,301	97,853	108,515

* Reclassified


The accompanying notes are an integral part of the interim condensed consolidated financial statements.

CONDENSED CONSOLIDATED BALANCE SHEETS U.S. dollars in thousands

	June 30,		December 31,
	2014	2013	2013
	Unaudited		Audited
LIABILITIES AND EQUITY			
CURRENT LIABILITIES:			
Credit from banks and current maturities	10,643	9,117	10,477
Deferred revenues	521	110	330
Trade payables	1,969	1,016	1,433
Other accounts payable	4,236	3,768	4,568
Other liabilities	1,526	-	2,504
	18,895	14,011	19,312
NON-CURRENT LIABILITIES:			
Long-term loans	16,496	18,965	18,205
Deferred revenues	1,218	1,272	1,283
Employee benefit liabilities	875	985	805
	18,589	21,222	20,293
Total liabilities	37,484	35,233	39,605
EQUITY:			
Issued capital	31	31	31
Additional paid-in capital	95,037	94,692	95,014
Treasury shares	(2,579)	(2,956)	(2,774)
Foreign currency translation reserve	6,213	3,622	6,148
Capital reserve for available-for sale investments and actuarial gains	1,175	892	1,633
Accumulated deficit	(31,060)	(33,661)	(31,142)
Total equity	68,817	62,620	68,910
Total liabilities and equity	106,301	97,853	108,515

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

August 19, 2014
Date of approval of the
financial statements


Elon Shalev
Chairman of the Board of Directors


Yariv Alroy
Co - CEO

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

U.S. dollars in thousands (except per share amounts)

	Three months ended		Six months ended		Year ended
	June 30,		June 30,		December 31,
	2014	2013	2014	2013	2013
	Unaudited				Audited
Revenues	10,274	7,408	20,917	14,548	29,674
Depreciation and amortization	562	551	1,166	1,122	2,127
Cost of revenues	3,947	2,963	8,007	5,859	11,607
Gross profit	5,765	3,894	11,744	7,567	15,940
Research and development costs, net	645	577	1,242	1,013	2,206
Selling and marketing expenses	2,987	2,328	5,719	4,679	8,787
General and administrative expenses	2,063	583	4,347	1,291	10,341
Gain from almeda acquisition and other income	(137)	-	(137)	-	(8,492)
Operating income	207	406	573	584	3,098
Financial income	511	141	704	474	1,072
Financial expenses	(370)	(407)	(614)	(1,052)	(2,631)
Income before taxes on income	348	140	663	6	1,539
Taxes on income (tax benefit)	269	82	581	293	(693)
Net income (loss)	79	58	82	(287)	2,232
Earnings (loss) per share:					
Basic and diluted income (loss) for the period	0.01	**	0.01	(0.03)	0.22
Other comprehensive income (loss) (net of tax effect):					
Other comprehensive income not to be reclassified to profit or loss in subsequent periods:					
Foreign currency translation reserve	301	620	65	1,562	4,088
Actuarial gain	-	-	-	-	233
	301	620	65	1,562	4,321
Other comprehensive income to be reclassified to profit or loss in subsequent periods:					
Transfer to the statement of income in respect of available-for-sale investments	(489)	13	(545)	(19)	146
Gain (loss) on available-for-sale investments	(87)	19	87	63	406
	(576)	32	(458)	44	552
Total other comprehensive income (loss)	(275)	652	(393)	1,606	4,873
Total comprehensive income (loss)	(196)	710	(311)	1,319	7,105

** Represents an amount lower than \$ 0.01

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

U.S. dollars in thousands

	Issued capital	Additional paid-in capital	Treasury shares	Foreign currency translation reserve	Capital reserve for available- for-sale Investments and actuarial gains**	Accumulated deficit	Total
	Audited						
Balance as of January 1, 2013	31	94,341	(2,920)	2,060	848	(33,374)	60,986
Purchase of treasury shares	-	-	(36)	-	-	-	(36)
Exercise of options	*) -	304	182	-	-	-	486
Share-based payments	-	369	-	-	-	-	369
Total comprehensive income	-	-	-	4,088	785	2,232	7,105
Balance as of December 31, 2013	31	95,014	(2,774)	6,148	1,633	(31,142)	68,910
Exercise of options	*) -	(130)	195	-	-	-	65
Share-based payments	-	153	-	-	-	-	153
Total comprehensive income (loss)	-	-	-	65	(458)	82	(311)
Balance as of June 30, 2014 (unaudited)	31	95,037	(2,579)	6,213	1,175	(31,060)	68,817

	Issued capital	Additional paid-in capital	Treasury shares	Foreign currency translation reserve	Capital reserve for available- for-sale Investments and actuarial gains	Accumulated deficit	Total
Balance as of January 1, 2013	31	94,341	(2,920)	2,060	848	(33,374)	60,986
Purchase of treasury shares	-	-	(36)	-	-	-	(36)
Exercise of options	*) -	141	-	-	-	-	141
Share-based payments	-	210	-	-	-	-	210
Total comprehensive income (loss)	-	-	-	1,562	44	(287)	1,319
Balance as of June 30, 2013 (unaudited)	31	94,692	(2,956)	3,622	892	(33,661)	62,620

* Represents an amount lower than \$ 1.

** As of June 30, 2014 the capital reserve for available for sale investments is in the amount of \$ 827 and the capital reserve on actuarial gains is in the amount of \$ 348.

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

U.S. dollars in thousands

	Issued capital	Additional paid-in capital	Treasury shares	Foreign currency translation reserve	Capital reserve for available- for-sale Investments and actuarial gains	Accumulated deficit	Total
	Unaudited						
Balance as of April 1, 2014	31	95,069	(2,753)	5,912	1,751	(31,139)	68,871
Exercise of options	*) -	(114)	174	-	-	-	60
Share-based payments	-	82	-	-	-	-	82
Total comprehensive income	-	-	-	301	(576)	79	(196)
Balance as of June 30, 2014	31	95,037	(2,579)	6,213	1,175	(31,060)	68,817

	Issued capital	Additional paid-in capital	Treasury shares	Foreign currency translation reserve	Capital reserve for available- for-sale Investments and actuarial gains	Accumulated deficit	Total
Balance as of April 1, 2013	31	94,488	(2,956)	3,002	860	(33,719)	61,706
Exercise of options	*) -	101	-	-	-	-	101
Share-based payments	-	103	-	-	-	-	103
Total comprehensive income	-	-	-	620	32	58	710
Balance as of June 30, 2013 (unaudited)	31	94,692	(2,956)	3,622	892	(33,661)	62,620

* Represents an amount lower than \$ 1.

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

	Three months ended		Six months ended		Year ended
	June 30,		June 30,		December 31,
	2014	2013	2014	2013	2013
	Unaudited				Audited
Cash flows from operating activities:					
Net income (loss)	79	58	82	(287)	2,232
Adjustments required to reconcile net income (loss) to net cash provided by (used in) operating activities:					
Income and expenses not involving operating cash flows:					
Depreciation and amortization	1,407	1,263	3,046	2,449	4,827
Capital gain from sale of property and equipment	-	(9)	-	(9)	(9)
Change in employee benefit liabilities, net	29	45	63	77	98
Financial expenses (income), net	(141)	266	(90)	578	1,559
Cost of share-based payments	82	103	153	210	369
Taxes on income	269	82	581	293	(693)
Gain from almeda acquisition	-	-	-	-	(8,492)
	1,646	1,750	3,753	3,598	(2,341)
Changes in operating assets and liabilities:					
Decrease (increase) in trade receivables, net	(691)	(313)	(4,327)	4,006	6,592
Increase in inventory	(395)	(17)	(750)	(95)	(409)
Decrease (increase) in prepaid expenses	(128)	225	(202)	2	(12)
Increase in other accounts receivable	(530)	(219)	(334)	(169)	(1,158)
Increase (decrease) in trade payables	281	(461)	(15)	(415)	30
Increase (decrease) in deferred revenues	(114)	(240)	111	(180)	(40)
Decrease in short and long-term other accounts payable	(922)	(1,449)	(1,475)	(3,089)	(1,823)
	(2,499)	(2,474)	(6,992)	60	3,180
Cash paid and received:					
Interest received	144	208	457	398	718
Interest paid	(242)	(281)	(526)	(560)	(1,110)
Income taxes paid	(13)	(25)	(32)	(37)	(47)
	(111)	(98)	(101)	(199)	(439)
Net cash provided by (used in) operating activities	(885)	(764)	(3,258)	3,172	2,632

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

	Three months ended		Six months ended		Year ended
	June 30,		June 30,		December 31,
	2014	2013	2014	2013	2013
	Unaudited				Audited
Cash flows from investing activities:					
Purchase of property and equipment	(480)	(315)	(863)	(918)	(2,200)
Investment in intangible assets	(380)	(501)	(778)	(986)	(1,878)
Restricted cash	(1,367)		(1,367)		
Acquisition of almeda (a)	-	-	-	-	2,920
Proceeds from sale of property and equipment	-	14	-	14	29
Purchase of short-term investments	(3,130)	(2,665)	(5,056)	(3,113)	(8,511)
Proceeds from sale of short-term investments	10,085	905	12,529	1,654	6,402
Net cash provided by (used in) investing activities	4,728	(2,562)	4,465	(3,349)	(3,238)
Cash flows from financing activities:					
Proceeds from exercise of options	60	101	65	141	486
Short-term bank credit, net	(714)	461	-	218	1,053
Payment of long-term loans	(998)	(804)	(1,867)	(1,580)	(3,267)
Treasury shares purchased	-	-	-	(36)	(36)
Net cash used in financing activities	(1,652)	(242)	(1,802)	(1,257)	(1,764)
Effect of exchange rate changes on cash and cash equivalents	24	56	17	278	489
Increase (decrease) in cash and cash equivalents	2,215	(3,512)	(578)	(1,156)	(1,881)
Cash and cash equivalents at the beginning of the period	5,939	12,969	8,732	10,613	10,613
Cash and cash equivalents at the end of the period	8,154	9,457	8,154	9,457	8,732

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

	Three months ended		Six months ended		Year ended
	June 30,		June 30,		December 31,
	2014	2013	2014	2013	2013
	Unaudited				Audited
(a) Acquisition of almeda:					
Working capital (excluding cash)	-	-	-	-	590
Receivables	-	-	-	-	(1,416)
Property and equipment, net	-	-	-	-	(361)
Contracts	-	-	-	-	(5,109)
Customer relations	-	-	-	-	(3,803)
Deferred taxes	-	-	-	-	2,023
Other liabilities	-	-	-	-	2,504
Gain from almeda acquisition	-	-	-	-	8,492
	-	-	-	-	2,920

(b) Non-cash transactions:

Purchase of property and equipment	443	180	541	315	134
------------------------------------	-----	-----	-----	-----	-----

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

NOTE 1 | GENERAL

These financial statements have been prepared in a condensed format as of June 30, 2014, and for the six months then ended. These financial statements are to be read in conjunction with the annual financial statements and accompanying notes of SHL Telemedicine Ltd. (“the Company”) as of December 31, 2013 and for the year then ended (“the annual financial statements”).

Following are data regarding the Israeli CPI and the exchange rates of the Euro, U.S. dollar and the Swiss Franc:

For the period ended	Israeli CPI Points	Exchange rate of € 1 NIS	Exchange rate of U.S. \$ 1 NIS	Exchange rate of 1 CHF NIS
June 30, 2014	223.8	4.69	3.438	3.863
June 30, 2013	222.7	4.72	3.618	3.823
December 31, 2013	223.8	4.78	3.47	3.89
Change during the period	%	%	%	%
June 2014 (6 months)	-	(1.8)	(0.9)	(0.7)
June 2013 (6 months)	1.3	(4.1)	(3.1)	(6.2)
June 2014 (3 months)	0.5	(2.5)	(1.4)	(2.1)
June 2013 (3 months)	1.3	1.2	(0.5)	-
December 2013 (12 months)	1.8	(2.8)	(6.9)	(4.4)

NOTE 2 | SIGNIFICANT ACCOUNTING POLICIES

a. Basis of preparation of the interim consolidated financial statements:

The interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles for the preparation of financial statements for interim periods, as prescribed in IAS 34, “Interim Financial Reporting.”

The significant accounting policies and methods of computation adopted in the preparation of the interim consolidated financial statements are consistent with those followed in the preparation of the annual financial statements.

NOTE 3 | TAXES ON INCOME

b. Financial assets at fair value through profit or loss

During the second quarter, the Company sold available for sale investments in the amount of \$ 9,122 thousands and purchased new investments in the amount of \$ 2,183 classified as financial assets designated upon initial recognition as at fair value through profit or loss.

Gains and losses of financial assets at fair value through profit or loss are recognized in profit and loss when incurred.

The following table shows the composition of the financial assets in the balance sheet:

	June 30,		December 31,
	2014	2013	2013
	Unaudited		Audited
Available for sale			
investments	10,118	18,091	19,661
Financial assets at fair value			
through profit or loss	2,183	-	-
	12,301	18,091	19,661

c. Disclosure of new IFRS standards in the period prior to their adoption:

IFRS 15, "Revenue from Contracts with Customers"

IFRS 15 ("the Standard") was issued by the IASB in May 2014.

IFRS 15 replaces IAS 18, "Revenue", IAS 11, "Construction Contracts, and the related Interpretations: IFRIC 13, "Customer Loyalty Programs", IFRIC 15, "Agreements for the Construction of Real Estate", IFRIC 18, "Transfers of Assets from Customers" and SIC-31, "Revenue - Barter Transactions Involving Advertising Services".

The Standard introduces a five-step model that applies to revenue from contracts with customers. IFRS 15 also establishes the accounting treatment of incremental costs involving obtaining a contract and the costs directly related to fulfilling a contract.

The Standard will apply retrospectively to annual periods beginning on or after January 1, 2017. Early adoption is permitted. The Standard may be applied to existing contracts beginning with the current period and thereafter. No restatement of the comparative periods will be required as long as comparative disclosures about the current period's revenues under existing IFRS are included.

The Company is evaluating the possible impact of the adoption of IFRS 15 but is presently unable to assess their effect, if any, on the financial statements.

On December 31, 2012, the Company was issued tax assessments in Israel for the years 2006-2008 in the aggregate amount of approximately \$ 9,300. The Company had contested the assessments and, on February 28, 2013, filed an appeal against them.

On February 27, 2014 the Company was issued an updated tax assessment in Israel in the amount of \$ 6,200.

On March 13, 2014 the Company filed an appeal.

NOTE 4 | SEGMENT INFORMATION

As discussed in the annual financial statements, the Group operates in three geographic segments: Israel, Europe and Rest of World. Revenues are allocated based on the location of the end customer.

Segments results:

a. Revenues:	Three months ended		Six months ended		Year ended
	June 30,		June 30,		December 31,
	2014	2013	2014	2013	2013

	Unaudited		Unaudited		Audited
Sales to external customers:					
Europe	4,116	1,595	8,704	3,052	6,058
Rest of world	12	-	12	-	-
Israel	6,146	5,813	12,201	11,496	23,616
Total revenues in financial statements	10,274	7,408	20,917	14,548	29,674

b. Segment profit:	Three months ended		Six months ended		Year ended
	June 30,		June 30,		December 31,
	2014	2013	2014	2013	2013

	Unaudited		Unaudited		Audited
Europe	595	547	1,456	786	6,076
Rest of world	(937)	(398)	(1,874)	(871)	(2,118)
Israel	1,280	896	2,401	1,812	1,658
	938	1,045	1,983	1,727	5,616
Corporate and R&D expenses	(731)	(639)	(1,410)	(1,143)	(2,518)
Operating income	207	406	573	584	3,098
Financial income (expenses), net	141	(266)	90	(578)	(1,559)
Income before taxes on income	348	140	663	6	1,539

Information For Investors

SHL TeleMedicine: profile

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. The Company operates in Israel, Germany, India and the United States in one business segment, Telemedicine services. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and has an ADR program listed over-the-counter; Symbol: SMDCY. For more information please visit our web site at www.shl-telemedicine.com

Capital structure

The issued share capital is divided into 10,455,800 registered shares with a par value of NIS 0.01 each (excluding 422,088 ordinary shares of NIS 0.01 par value each held by SHL).

Significant shareholders'

As of June 30, 2014, SHL was aware of the following shareholders with more than 3% of all voting rights in the company.

	Number	% Including Treasury shares	% Excluding Treasury shares
Alroy Group	2,782,608	25.58%	26.61%
G.Z. Assets and Management Ltd.	921,533	8.47%	8.81%
Prime Finance Corporation	736,722	6.77%	7.05%
Copper Valley Finance Ltd.	736,722	6.77%	7.05%
Eli Alroy	749,299	6.89%	7.17%
SHL Treasury shares	422,088	3.88%	-


The above table of Significant Shareholders reflects both actual holdings as of June 30, 2014, after deducting from the total number of shares outstanding 422,088 Ordinary Shares held by SHL, and actual holdings as of June 30, 2014 calculated including ordinary shares held by SHL, all as indicated above, but does not reflect holdings on a fully diluted basis. All in accordance with notifications received by the Company from shareholders and the SAG registrar as of June 30, 2014.

SHL Telemedicine: share-price development Statistics on SHL Telemedicine as at June 30, 2014

Registered shares with a par value of NIS 0.01 each

Securities number	1128957
Number of shares*	10,455,800
Market price high/low (CHF)	9.78/6.97
Market capitalization high/low (CHF million)	106.4/75.8
Market capitalization 30/6/2014 (CHF million)	91.4
Share capital – nominal value (NIS)*	104,558
Majority interests	26.61%

* Excluding 422,088 ordinary shares held by SHL



Listing

All SHL shares are listed on SIX Swiss Exchange

Ticker symbol:	SHLTN
Currency:	CHF
Listing date:	November 15, 2000
Company has and ADR program on the OTCBB. Ticker symbol:	SMDCY

Investor relations

SHL Telemedicine Ltd.

Erez Alroy, Co-CEO

Eran Antebi, CFO

90 Igal Alon St., Tel Aviv 67891, Israel

Tel. ++972 3 561 2212

Fax: ++972 3 624 2414

Email: ereza@shl-telemedicine.com

Email: erana@shl-telemedicine.com

Next publications

Q3 Results: November 19, 2014